Abstract: Provided are bicyclic oxa-lactam compounds of formula I: and pharmaceutically acceptable salts thereof which are inhibitors of JAK/Syk kinase. The present disclosure is also directed to intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting JAK/Syk kinase activity, and methods for treating conditions mediated at least in part by JAK/Syk kinase activity.

Abstract: Disclosed is a method of preparing an amino acid ester of maytansinol by reacting maytansinol with an N-carboxyanhydride of an amino acid (NCA) in the presence of a drying agent. Also disclosed is an improved method of preparing an amino acid ester of maytansinol in which a nucleophile is added to the reaction mixture after completion of the reaction between maytansinol and an N-carboxyanhydride of an amino acid.

Abstract: Largazole analogs, methods of making the same, and methods of using the same, are described.

Abstract: Novel compounds of formula (I) wherein R1 to R4 and X have the meaning according to the claims, are glucosidase inhibitors, and can be employed, inter alia, for the treatment of Alzheimer's disease.

Abstract: A novel class of lanthanide metal salen complexes can be used as an ingredient of a catalyst system. The catalyst system can be used in polymerizations of ethylenically unsaturated hydrocarbon monomers.

Abstract: A method of treating a disease comprising administering to a subject a therapeutically effective amount of a compound that includes the structure of general Formula II, pharmaceutically acceptable salts thereof, and/or solvates thereof: wherein R1, R2, R3, are independently selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together form a cyclic boronate ester and R3 is null; wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation that is potassium or sodium, X1, X2, X3, and X4 are independently selected from the group consisting of O, CH, and N, with the proviso that no more than two of combined O and N are selected, and Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.

Abstract: Materials which react with (“scavenge”) sulfur compounds, such as hydrogen sulfide and mercaptans, are useful for limiting sulfur-induced corrosion. Surface-modified particles incorporating a hexahydrotriazine moiety are disclosed and used as sulfur scavengers. These surface-modified particles are used a filter media in fixed filter systems and as additives to fluids including sulfur compounds. The hexahydrotriazine moiety can react with sulfur compounds in such a manner as to bind sulfur atoms to the surface-modified particles, thus allowing removal of the sulfur atoms from fluids such as crude oil, natural gas, hydrocarbon combustion exhaust gases, sulfur polluted air and water. The surface-modified particles may, in general, be sized to allow separation of the particles from the process fluid by sedimentation, size-exclusion filtration or the like.

Abstract: Vulcanizates with desirable properties can be obtained from compounds incorporating polymers that include hydroxyl group-containing ?-methylstyrene functionalities. The functionalities can be incorporated by using any or all of appropriate initiators, monomers and optional terminating compounds. Such polymers exhibit excellent interactivity with both conventional and non-conventional fillers.

Abstract: The present invention relates to a process for preparing optically active bisphosphinylalkanes from the correspondingly substituted, racemic 1,2-diols. The optically active bisphosphinylalkanes which can be obtained in this way are suitable as ligands for preparing chiral transition metal catalysts.

Abstract: The present invention relates to an acrylic pressure-sensitive adhesive composition, a polarizing plate and a liquid crystal display device, using the same. More specifically, the present invention relates to an acrylic pressure-sensitive adhesive composition having optimal stress releasing property which comprises an optically compensated acrylic copolymer (A) containing a cross-linkable functional group, an optically compensated acrylic copolymer (B) containing no cross-linkable functional group, and a multi-functional cross-linking agent (C). A polarizing plate and a liquid crystal display device comprising the pressure-sensitive adhesive composition meets with major properties such as adhesion endurance reliability, with effectively providing optical compensation effect and stress release effect, and has an effect of improving a light leakage phenomenon.

Abstract: Oligonucleotide analogs comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

Abstract: The object of the present invention is to provide a compound having a lysophosphatidylserine receptor function modulation activity or a salt thereof. A compound having a lysophosphatidylserine receptor function modulation activity or a salt thereof, or a pharmaceutical composition or a lysophosphatidylserine receptor function moderator containing such compound or salt is provided by the present invention.

Abstract: The present invention concerns synthesizing manganese complexes in essentially non-aqueous solutions.

Abstract: The present invention relates to metal complexes and to electronic devices, in particular organic electroluminescent devices, comprising these metal complexes.

Abstract: The present disclosure relates to a ferromagnetic substance containing a crystal of a metal complex molecule in which a heterocycle is bonded to metal, the metal of the metal complex molecule is bonded to the metal of another metal complex via oxygen as a electron donor, and the ferromagnetic substance has a ferromagnetic property balanced with stability of crystals based on a metal-electron donor-metal bond angle that is from 130° to 160°. The present disclosure also relates to a drug containing, as a principal component, the crystal of the metal complex molecule.

Abstract: Glucocorticosteroids that are derivatives of isoxazolidine are useful as anti-inflammatory and antiallergic compounds of the glucocorticosteroid series.

Abstract: Populations of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the scaffold amino acid sequence EXXXAXXEIX XLPNLTXXQX XAFIXKLXDD PSQSSELLSE AKKLNDSQ (SEQ ID NO: 1) or AKYAKEXXXAXX EIXXLPNLTX XQXXAFIXKL XDDPSQSSEL LSEAKKLNDS Q (SEQ ID NO:2), wherein each X individually corresponds to an amino acid residue which is varied in the population are disclosed. Also populations of polynucleotides, wherein each member encodes a member of a polypeptide population are disclosed. Furthermore, combinations of such polypeptide populations and such polynucleotide populations are disclosed, wherein each member of polypeptide population is physically or spatially associated with the polynucleotide encoding that member via means for genotype-phenotype coupling.

Abstract: Single-use closed bioreactors with recirculating exhaust gas that can be operated in an uncontrolled environment are reported for the manufacturing of biological products using genetically modified biological cultures that produces carbon dioxide or that requires carbon dioxide in their metabolic process.

Abstract: This invention relates to the application of hydroxyapatite chromatography to the purification of at least one antibody from a preparation containing high molecular weight aggregates. Further, this invention relates to an integration of ceramic hydroxyapatite chromatography into a combination chromatographic protocol for the removal of high molecular weight aggregates from an antibody preparation.

Abstract: The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern at values of two theta (° 2?) of 10.7, 11.6, 12.7, 13.0, 13.2, 13.7, 14.5, 18.7, 19.0, and 19.9 after equilibration at 43% relative humidity.

Abstract: The present invention provides a novel ?-conotoxin peptide, pharmaceutical composition and use thereof. The present invention further provides a propeptide of the conotoxin peptide, a nucleic acid construct, expression vector and transformed cell of the conotoxin peptide as well as a fused protein of the conotoxin peptide. The present invention discloses a method for blocking acetylcholine receptors as well as a use of the conotoxin peptide in the manufacture of a medicament. The ?-conotoxin peptide of the present invention can specifically block acetylcholine receptor (nAChRs, such as ?3?2 nAChRs, ?6/?3?2?3 nAChR or ?3?4 nAChR or ?6/?3?4 nAChR), has activity for treatment of neuralgia, addiction, Parkinson's disease, dementia, schizophrenia, cancers, and can be used in the manufacture of a medicament for analgesia and smoking cessation and drug-withdrawal, a medicament for treatment of mental diseases and cancers, as well as a tool drug for neurosciences.

Abstract: The present disclosure relates to anti-inflammatory proteins, their uses, methods of preparation and methods of their detection. In particular, the invention relates to major royal jelly proteins modified by methyglyoxal and fragments thereof from manuka honey.

Abstract: The application provides Fc fusion proteins having novel arrangements. In one embodiment, the application provides Fc fusion proteins comprising a 10Fn3 domain. In another embodiment, the application provides Fc fusion proteins comprising linkers derived from the naturally occurring C-terminal tail regions of membrane bound or secretory immunoglobulins.

Abstract: The invention relates to biomimetic peptide-containing compositions for use, in particular, for application and or deposition on a magnesium alloy, e.g., substrate, to at least partially coat a surface of the magnesium alloy. The invention also relates to the coated magnesium alloy which is particularly useful for tissue and bone repair and regeneration applications, such as, for constructing medical implant devices.

Abstract: The invention relates to peptides which consist of amino acid sequences found in the NY-ESO-1 molecule, which bind to MHC-Class II molecules. These can be used alone, or in combination with other peptides.

Abstract: Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease.

Abstract: Mutant fibroblast growth factor (FGF) proteins having a polypeptide sequence with a high sequence identity to proteins encoded by members of the Fgf-1 subfamily of genes from a mammalian species, such as human, and with a specific amino acid substitution of an alanine at a position corresponding to amino acid position 66 of human FGF-1 with a cysteine and/or a specific amino acid substitution of a phenylalanine at a position corresponding to amino acid position 132 of human FGF-1 with a tryptophan (based on the 140 amino acid numbering scheme of human FGF-1) are provided. Other amino acid mutations or substitutions may be combined. Polynucleotide sequences encoding the mutant FGF proteins and host cells containing such polynucleotide sequences are provided. Methods of administering a mutant FGF protein to an individual to treat an ischemic condition or disease or a wound or tissue injury are also provided.

Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.

Abstract: This document provides aquaretic and natriuretic polypeptides. For example, this document provides polypeptides having aquaretic and/or natriuretic activities. In some cases, a polypeptide provided herein can have aquaretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing aquaretic and/or natriuretic activities within a mammal.

Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.

Abstract: The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC). The invention provides a method of activating a signaling pathway and/or killing a cancer cell using a receptor that is similar to or is a T cell receptor.

Abstract: Antibodies or antibody fragments, wherein the antibody or the fragment binds HA domain of influenza virus (e.g. H1N1, H5N1, or both). Also described are cloned human antibodies that bind influenza.

Abstract: Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.

Abstract: The invention relates to binding partners of the placental growth factor (or placenta growth factor, PIGF), especially antibodies directed against the placental growth factor, and production and use thereof.

Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.

Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospholipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.

Abstract: Antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. A composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.

Abstract: This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.

Abstract: There is disclosed a process for the derivatization of cellulose comprising the sequential steps: a) mixing cellulose with a viscosity below 900 ml/g with an aqueous solution to obtain a liquid, wherein particles comprising cellulose in said liquid have a diameter of maximum 200 nm, wherein the temperature of the aqueous solution is below 20° C., and wherein the pH of the aqueous solution is above 12, b) subjecting the liquid to at least one of the steps: i) decreasing the pH of the liquid with at least 1 pH unit, ii) increasing the temperature by at least 20° C., and c) derivatization of the cellulose. Advantages include that there is provided the possibility to derivatize cellulose faster and to a greater extent after the treatment. Further the yield is improved. The product quality is improved and the manufacture is cheaper and easier.

Abstract: Disclosed are a method of preparing acetylated cellulose ether, and acetylated cellulose ether prepared thereby. Here, the disclosed method of preparing the acetylated cellulose ether includes dissolving acetylated cellulose ether in an organic solvent to obtain a mixture comprising a solution of the acetylated cellulose ether; removing an insoluble component that is insoluble in the organic solvent from the mixture; and adding the mixture to water to precipitate the acetylated cellulose ether. The acetylated cellulose ether prepared thereby has a turbidity of less than 40 formazin turbidity units (FTU).

Abstract: The present invention relates to a process for producing microcellulose comprising hydrolyzing fibrous cellulosic material with an acid at an elevated temperature or acidifying fibrous cellulosic material followed by washing and hydrolyzing the washed cellulosic material at an elevated temperature to produce a microcellulose-hydrolysate mixture followed by separation of the microcellulose from the hydrolysate, wherein the mixture or separated hydrolysate or microcellulose is optionally neutralized, and wherein the microcellulose production is integrated to production of a pulp mill such that at least part of chemicals used in the acidification, acid hydrolysis and/or neutralization is produced by an integrated chemical recovery process of the pulp mill.

Abstract: The invention relates to a method for processing an aqueous gel of nanofibrillar cellulose by removing water from the aqueous gel by means of an organic solvent miscible with water. In the method: aqueous gel is introduced into a volume of organic solvent miscible with water in a controlled manner so that the aqueous gel is kept as a separate phase and forms discrete physical entities containing the nanofibrillar cellulose within the phase; water is changed with the organic solvent in said discrete physical entities of nanofibrillar cellulose; and the physical entities are separated from the volume of organic solvent.

Abstract: The present invention relates to specific water and solvent-free nitrile rubbers having specific functional groups and/or end groups, a process for the production thereof and the use thereof. This process involves removing volatile compounds from a fluid (F) containing (1) at least one nitrile rubber and (2) at least one volatile compound, wherein the process comprises at least the steps of a.) treating the fluid (F) in at least one conversation unit, b.) retreating the concentrated fluid from step a.) in at least one retreating unit and c.) feeding the retreated concentrated fluid from step b.) into at least one retreating unit.

Abstract: Processes of forming polyolefins are described herein. One or more specific embodiments of the processes generally include introducing olefin monomer selected from C2-C3 olefins into a first reaction zone under first polymerization conditions to form a first polyolefin; withdrawing a transfer effluent from the first reaction zone, the transfer effluent including first polyolefin and unreacted olefin monomer; introducing the transfer effluent, a comonomer selected from C4-C8 olefins, and additional olefin monomer to a second reaction zone under second polymerization conditions to form a second reactor product; maintaining an essentially constant comonomer:olefin monomer ratio in the second reaction zone; and withdrawing at least a portion of the second reactor product, wherein the second reactor product includes a bimodal polyolefin.

Abstract: An asymmetric complex of formula (I) wherein M is zirconium or hafnium; each X is a sigma ligand; L is a divalent bridge selected from —R?2C—, —R?2C—CR?2—, —R?2Si—, —R?2Si—SiR?2—, —R?2Ge—, wherein each R? is independently a hydrogen atom, C1-C20-alkyl, tri(C1-C20-alkyl)silyl, C6-C20-aryl, C7-C20-arylalkyl or C7-C20-alkylaryl; R2 and R2? are each independently a C1-C20 hydrocarbyl radical; R5? is a C1-20 hydrocarbyl group; R5 is hydrogen, or a C1-20 hydrocarbyl group; R6 is a non tertiary C1-10 alkyl group or C6-10-aryl group or C7-10 arylalkyl group or ZR3; R6? is a tertiary C4-20 alkyl group; Z is O or S; R3 is a C1-20 hydrocarbyl group optionally substituted with halo; Ar is an aryl or heteroaryl group having up to 20 carbon atoms optionally substituted by one or more groups R1; Ar? is an aryl or heteroaryl group having up to 20 carbon atoms optionally substituted by one or more groups R1; each R1 is a C1-20 hydrocarbyl group or two R1 groups on adjacent carbon atoms taken together can form a fused 5

Abstract: A process for the polymerization of at least one olefin comprising reacting said at least one olefin with a catalyst comprising: (i) a metallocene complex said metallocene comprising at least two cyclopentadienyl type ligands; (ii) a boron cocatalyst; and (iii) an aluminoxane cocatalyst; said catalyst being in solid form, preferably in solid particulate form, and being free from an external carrier.

Abstract: The present invention provides a polyolefin powder including a homopolymer of ethylene or a copolymer of ethylene and an ?-olefin having 3 to 15 carbon atoms.

Abstract: Disclosed herein are catalyst compositions containing boron-bridged, cyclopentadienyl-fluorenyl metallocene compounds with an alkenyl substituent. These catalyst compositions can be used for the polymerization of olefins. For example, ethylene copolymers produced using these catalyst compositions can be characterized by a combination of a flat or a conventional comonomer distribution and low levels of long chain branching.

Abstract: A process and apparatus for producing olefin polymers are disclosed, comprising: a. polymerizing one or more olefins in the gas phase, in the presence of an olefin polymerization catalyst, whereby growing polymer particles flow along a cylindrically-shaped downward path in densified form under the action of gravity so as to form a densified bed of downward-flowing polymer particles b. allowing said polymer particles to flow through a restriction of the densified bed, such restriction being positioned in a restriction zone extending from the bed upward to a distance of 15% of the total height of the densified bed; and c. metering an antistatic agent through a feed line connected to the densified bed at a feed point being located in a feed zone extending from the top of the restriction upward, to a distance five times the diameter of the section of the densified bed above the restriction.